166
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Association of Serum Periostin Level with Classical Bone Turnover Markers and Bone Mineral Density in Shanghai Chinese Postmenopausal Women with Osteoporosis

, , , &
Pages 7639-7646 | Published online: 03 Nov 2021

References

  • Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277(6):650–661. doi:10.1111/joim.12369
  • Youness ER, Mohammed NA, Morsy FA. Cadmium impact and osteoporosis: mechanism of action. Toxicol Mech Methods. 2012;22(7):560–567. doi:10.3109/15376516.2012.702796
  • Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382–387. doi:10.14740/jocmr2970w
  • Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1–2):136. doi:10.1007/s11657-013-0136-1
  • Maggi S, Noale M, Giannini S, et al. Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int. 2006;17(2):237–244. doi:10.1007/s00198-005-1985-2
  • Cui Z, Meng X, Feng H, et al. Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Arch Osteoporos. 2019;15(1):2. doi:10.1007/s11657-019-0670-6
  • Kanis JA.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368–381. doi:10.1007/BF01622200
  • Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–1112. doi:10.1001/archinte.164.10.1108
  • Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202. doi:10.1016/j.bone.2003.10.001
  • Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4):97–122.
  • Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi:10.1007/s00198-010-1501-1
  • Chopin F, Biver E, Funck-Brentano T, et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine. 2012;79(1):26–31. doi:10.1016/j.jbspin.2011.05.004
  • Szulc P, Garnero P, Marchand F, Duboeuf F, Delmas PD. Biochemical markers of bone formation reflect endosteal bone loss in elderly men–MINOS study. Bone. 2005;36(1):13–21. doi:10.1016/j.bone.2004.09.004
  • Seeman E. The periosteum–a surface for all seasons. Osteoporos Int. 2007;18(2):123–128. doi:10.1007/s00198-006-0296-6
  • Bonnet N, Garnero P, Ferrari S. Periostin action in bone. Mol Cell Endocrinol. 2016;432:75–82. doi:10.1016/j.mce.2015.12.014
  • Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014;66:46–55. doi:10.1016/j.bone.2014.05.016
  • Contié S, Voorzanger-Rousselot N, Litvin J, et al. Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int. 2010;87(4):341–350. doi:10.1007/s00223-010-9391-y
  • Anastasilakis AD, Polyzos SA, Makras P, et al. Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. Horm Metab Res. 2014;46(2):145–149.
  • Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014;99(7):2533–2539. doi:10.1210/jc.2013-3893
  • Kim BJ, Rhee Y, Kim CH, et al. Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: clinical evidence for the different effects of periostin depending on the skeletal site. Bone. 2015;81:435–441. doi:10.1016/j.bone.2015.08.014
  • Farrokhi M, Arjaki D, Peykanpour F. Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women. Osteoporos Int. 2020;31(10):2061. doi:10.1007/s00198-020-05606-7
  • Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23(4):1199–1212. doi:10.1007/s00198-011-1892-7
  • Heo SC, Shin WC, Lee MJ, et al. Periostin accelerates bone healing mediated by human mesenchymal stem cell-embedded hydroxyapatite/tricalcium phosphate scaffold. PLoS One. 2015;10(3):e0116698. doi:10.1371/journal.pone.0116698
  • Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14(7):1239–1249. doi:10.1359/jbmr.1999.14.7.1239
  • Li C, Li X, Wang X, et al. Periostin mediates oestrogen-induced osteogenic differentiation of bone marrow stromal cells in ovariectomised rats. Biomed Res Int. 2020;2020:9405909.
  • Chung KW, Kim MR, Yoo SW, et al. Can bone turnover markers correlate bone mass at the hip and spine according to menopausal period? Arch Gynecol Obstet. 2000;264(3):119–123. doi:10.1007/s004040000093
  • Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337–349. doi:10.1002/jbmr.5650110307
  • Ghimire S, Miramini S, Edwards G, et al. The investigation of bone fracture healing under intramembranous and endochondral ossification. Bone Rep. 2021;14:100740. doi:10.1016/j.bonr.2020.100740
  • Gossiel F, Scott JR, Paggiosi MA, et al. Effect of teriparatide treatment on circulating periostin and its relationship to regulators of bone formation and BMD in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2018;103(4):1302–1309. doi:10.1210/jc.2017-00283